Oxygen
Raynaud Syndrome
Jay C. Buckey Jr.Small moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Raynaud Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Iloprost National Center for Research Resources (NCRR) | Phase 3 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Jose Soberon, MD | Phase 2/3 | B |
pf-00489791 Pfizer | Phase 2 | B |
Selexipag Actelion | Phase 2 | B |
Inomax RoseLab Skin Optics Laboratory | NR |
Same molecule, other indications
Oxygen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →